Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins
- Thursday, April 1, 2021, 7:10
- Environment
- Add a comment
DALLAS, April 1, 2021 /PRNewswire/ — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform oncology drug discovery and development, today announced a collaboration with Johns…
About the Author
adminasapcorp has written 39120 stories on this site.